Cited by 933Metabolism, Diabetes, and CancerDiabetes Treatment and ManagementDiabetes Management and Research

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Increased Cancer-Related Mortality for Patients With Type 2 Diabetes Who Use Sulfonylureas or Insulin

Open access

Bowker, Samantha L., Majumdar, Sumit R., Veugelers, Paul, Johnson, Jeffrey A.·2006·Diabetes Care

Open this paper in CoChat — free account Open PDF

Abstract

OBJECTIVE—Numerous studies have identified an increased risk of cancer in type 2 diabetes. We explored the association between antidiabetic therapies and cancer-related mortality in patients with type 2 diabetes, postulating that agents that increase insulin levels might promote cancer. RESEARCH DESIGN AND METHODS—This was a population-based cohort study using administrative databases from Saskatchewan Health. Cancer-related mortality was compared among inception cohorts of metformin users and sulfonylurea monotherapy users. Multivariate Cox regression was used to estimate the hazard ratio (HR) of cancer-related mortality, after adjusting for age, sex, insulin use, and chronic disease score. All statistical tests were two-sided. RESULTS—We identified 10,309 new users of metformin or sulfonylureas with an average follow-up of 5.4 ± 1.9 years (means ± SD). The mean age for the cohort was 63.4 ± 13.3 years, and 55% were men. Cancer mortality over follow-up was 4.9% (162 of 3,340) for sulfonylurea monotherapy users, 3.5% (245 of 6,969) for metformin users, and 5.8% (84 of 1,443) for subjects who used insulin. After multivariate adjustment, the sulfonylurea cohort had greater cancer-related mortality compared with the metformin cohort (adjusted HR 1.3 [95% CI 1.1–1.6]; P = 0.012). Insulin use was associated with an adjusted HR of cancer-related mortality of 1.9 (95% CI 1.5–2.4; P < 0.0001). CONCLUSIONS—Patients with type 2 diabetes exposed to sulfonylureas and exogenous insulin had a significantly increased risk of cancer-related mortality compared with patients exposed to metformin. It is uncertain whether this increased risk is related to a deleterious effect of sulfonylurea and insulin or a protective effect of metformin or due to some unmeasured effect related to both choice of therapy and cancer risk.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.2337/diacare.29.02.06.dc05-1558

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Metformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388
Metformin
Bailey, C. J., & Turner, R. C. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602293340906 · Cited by 1,726
Complexes between the LKB1 tumor suppressor, STRADα/β and MO25α/β are upstream kinases in the AMP-activated protein kinase cascade
Hawley, S. A., Boudeau, J., Reid, J. L., Mustard, K. J., Udd, L., Mäkelä, T. P., Alessi, D. R., & Hardie, D. G. (2003) · Journal of Biology · doi:10.1186/1475-4924-2-28 · Cited by 1,694
Efficacy of Metformin in Patients with Non-Insulin-Dependent Diabetes Mellitus
DeFronzo, R. A., & Goodman, A. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508313330902 · Cited by 1,368
A chronic disease score from automated pharmacy data
Korff, M. V., Wagner, E. H., & Saunders, K. W. (1992) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(92)90016-g · Cited by 962
Insulin and colon cancer
Giovannucci, E. L. (1995) · Cancer Causes & Control · doi:10.1007/bf00052777 · Cited by 808
Diabetes Mellitus as a Predictor of Cancer Mortality in a Large Cohort of US Adults
Coughlin, S. S., Calle, E. E., Teras, L. R., Petrelli, J. M., & Thun, M. J. (2004) · American Journal of Epidemiology · doi:10.1093/aje/kwh161 · Cited by 795
Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis
Everhart, J. (1995) · JAMA · doi:10.1001/jama.273.20.1605 · Cited by 747
Decreased Mortality Associated With the Use of Metformin Compared With Sulfonylurea Monotherapy in Type 2 Diabetes
Johnson, J. A., Majumdar, S. R., Simpson, S. H., & Toth, E. L. (2002) · Diabetes Care · doi:10.2337/diacare.25.12.2244 · Cited by 421
Self-citation
Prospective Study of Adult Onset Diabetes Mellitus (Type 2) and Risk of Colorectal Cancer in Women
Hu, F. B., Manson, J. E., Liu, S., Hunter, D. J., Colditz, G. A., Michels, K. B., Speizer, F. E., & Giovannucci, E. L. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.6.542 · Cited by 420

Show all 37 references

Sorted by citations

Items 801–900 of 933

Metformin and Its Implication in Cancer Therapy
Mazilu, L., Stănculeanu, D. L., Gheorghe, A. D., Suceveanu, A., Parepa, I. R., Voinea, F., Catrinoiu, D., & Suceveanu, A. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.88803 · Cited by 1
Cancer Risk in Patients with Type 2 Diabetes on Antidiabetic Monotherapy: A Population Based Cohort Study Using National Insurance Health Service Database
Jung, H. Y., & Lee, S. (2019) · Korean Journal of Clinical Pharmacy · doi:10.24304/kjcp.2019.29.3.186 · Cited by 1
Pharmacological interventions part IV: Metabolic modifiers
Koltai, T., Reshkin, S. J., & Harguindey, S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819059-3.00016-2 · Cited by 1
Metformina – cudowny lek?
Bauer, A. (2017) · TU repository (Lodz University of Technology) · Cited by 1
Risk factors for papillary thyroid cancer in obesity and diabetes mellitus
Gychka, S. G., Serbin, B. Y., Nikolaenk, S. I., Matviian, M. A., Sujima, S., & Товкай, О. А. (2020) · Clinical endocrinology and endocrine surgery · doi:10.30978/cees-2020-3-85 · Cited by 1
Antitumor Effect of Metformin in Combination with Binimetinib on Melanoma Cells
Lee, E., Kwon, Y., Kim, J., Park, D., & Lee, Y. (2021) · Development & Reproduction · doi:10.12717/dr.2021.25.2.93 · Cited by 1
Diabetes and Cancer
Vigneri, R., & Sciacca, L. (2018) · Endocrinology · doi:10.1007/978-3-319-44433-8_12 · Cited by 1
Effect of Metformin Therapy on Biological Properties and Prognosis of Breast Cancer Patients Complicated with Type-2 Diabetes
Yan, X., Gao, Z., Li, Y., Li, Q., & Deng, X. (2022) · Pakistan Journal of Medical Sciences · doi:10.12669/pjms.38.5.5135 · Cited by 1
Innovations in Post-Marketing Safety Research
Stefansdottir, G. (2012) · Utrecht University Repository (Utrecht University) · Cited by 1
Hepatocellular cancer risk in diabetes: Not all diabetics are the same
Singh, S., & Singh, P. P. (2013) · Hepatology · doi:10.1002/hep.26452 · Cited by 1
Developing new comorbidity indices for cancer populations using administrative data
Sarfati, D. (2013) · Otago University Research Archive (University of Otago) · Cited by 1
Confirmation of the role of diabetes in the local recurrence of surgically resected non-small cell lung cancer.
Recht, A., Varlotto, J. M., Medford-Davis, L. N., Schaefer, É., Flíckinger, J. C., & Decamp, M. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.7069 · Cited by 1
Avaliação do efeito citotóxico da metformina em linhagens celulares de adenocarcinoma de próstata e de feocromocitoma
Meireles, C. G. (2015) · RIUnB Institutional Repository (University of Brasília) · doi:10.26512/2015.02.d.18424
Aspetti epidemiologici delle neoplasie nel diabete
Nicolucci, A. (2007) · L Endocrinologo · doi:10.1007/bf03344578
Patienten mit einer Metformin-Medikation seit Beginn ihrer Erkrankung haben ein geringes Risiko für das Auftreten einer Krebserkrankung
Jecht, M. (2009) · Der Diabetologe · doi:10.1007/s11428-009-0514-x
Targeting the mTOR signalling pathway for prevention and therapy of tuberous sclerosis in mouse models
Kalogerou, M. (2013) · ORCA Online Research @Cardiff (Cardiff University)
Pre-Clinical and Clinical Investigation of the Impact of Obesity on Ovarian Cancer Pathogenesis
Bae-Jump, V. L. (2015)
Diabetes und Karzinomrisiko des Verdauungstrakts: Update 2012
Jf, R. (2013) · Journal für Kardiologie (Krause & Pachernegg GmbH)
Antidiabetika und Krebsrisiko beim Pankreaskarzinom
Raddatz, D. (2010) · Die Gastroenterologie · doi:10.1007/s11377-010-0497-6
Non-incretin insulin secretagogues for patients with type 2 diabetes mellitus
Hemmingsen, B., Lundstrøm, L. H., Hemmingsen, C., Lund, S. S., Wetterslev, J., Gluud, C. N., Vaag, A. A., & Almdal, T. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009008
Retracted
Emerging Therapies for Esophageal Cancer
Orita, H., Brock, M. V., & Sato, K. (2012) · InTech eBooks · doi:10.5772/30655
Determining the Role of Autophagy in HER2/neu-Induced Mammary Tumor Dormancy and Recurrence
Dwyer, S. (2013) · Scholarly Commons (University of Pennsylvania)
Strategies for Targeting Cancer Stem Cells
Mufson, R. A. (2015) · Wiley-VCH eBooks · doi:10.1002/3527600906.mcb.201500001
Myocardial infarction and diabetes mellitus Studies on glucose lowering therapies and novel risk markers based on observations from the DIGAMI 2 trial
Mellbin, L. (2010) · Figshare
Quantifying the associations between diabetes mellitus, glycated haemoglobin and incidence of and mortality from cancer: analysis of longitudinal data from England and Scotland linked to Cancer Registry and mortality data
Gordon-Dseagu, V. (2014) · UCL Discovery (University College London)
Effects of consumption of a cashew drink (Anacardium occidentale) on glucose-insulin response in patients with type 2 diabetes mellitus
Domínguez, M. J. R., Henríquez, A. R. B., Sintjago, E. A. M., & Ferrer, E. K. E. (2012) · Vitae (Universidad de Antioquia)
Praktyczne wskazówki dotyczące rozpoznawania i leczenia zaburzeń metabolizmu glukozy u osób z chorobą nowotworową
Zozulińska‐Ziółkiewicz, D., Wysocki, P. J., & Wierusz‐Wysocka, B. (2010) · Onkologia w Praktyce Klinicznej
Insulin-increasing diabetes therapies raise risk of death from cancer
Sole, K. (2006) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0146
M1968 Metformin Disrupts Crosstalk Between G Protein-Coupled Receptor and Insulin Receptor Signaling Systems and Inhibits Pancreatic Cancer Growth
Kisfalvi, K., Young, S. H., Sinnett‐Smith, J. W., Eibl, G., & Rozengurt, E. (2010) · Gastroenterology · doi:10.1016/s0016-5085(10)62078-1
Should we consider cancer diagnosis in diabetic patients as a complication of diabetes, or is it iatrogenic sequelae?
Tuomilehto, J. (2012) · Primary care diabetes · doi:10.1016/j.pcd.2012.01.006
Quelles hormones promeuvent le cancer du sein en post-ménopause : estrogènes, progestatifs, insuline et/ou adipocytokines ?
Jamin, C. (2009) · Gynécologie Obstétrique & Fertilité · doi:10.1016/j.gyobfe.2009.11.004
Metformin: a pharmacological approach integrating hyperinsulinemia breast cáncer at the molecular, cellular clinical levels
Martı́n-Castillo, B., Vázquez‐Martín, A., Oliveras‐Ferraros, C., & Menéndez, J. A. (2010) · Avances en Diabetología · doi:10.1016/s1134-3230(10)62003-0
Des traitements adaptés à la physiopathologie du diabète de type 2
Sacoun, E. (2011) · Option/Bio · doi:10.1016/s0992-5945(11)70783-8
Luces y sombras en la aplicación de las nuevas guías para el tratamiento de la diabetes mellitus tipo 2. Consejos prácticos sobre el tratamiento combinado y la insulinoterapia
Sánchez, O., & Ruiz, J. S. (2008) · Medicina Clínica · doi:10.1157/13116324
Neoadjuvant chemotherapy for breast cancer: a role for short-term fasting?
Niu, J., & Weiss, G. J. (2013) · Breast Cancer Management · doi:10.2217/bmt.13.49
No “Barge in” on “Glargine”!
SADIKOT, S. M., Sosale, A., Nigam, A., Ahmed, J., Singh, S., Zargar, A. A. Z., Misra, A., Prasannakumar, K. M., WANGNOO, S. K., Makker, B., et al. (2009) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2009.08.002
Intensieve glucoseregulering en het risico op kanker bij type 2 diabetes: een meta-analyse van belangrijke trials
Johnson, J. A., & Bowker, S. L. (2011) · Nederlands Tijdschrift voor Diabetologie · doi:10.1007/s12467-011-0017-4
Self-citation
Repositioned alpha-1 adrenoceptor blockers as anti-tumor drugs
Nagaya, H., Nakagawa, Y. U., & Gotoh, A. (2015) · Personalized Medicine Universe · doi:10.1016/j.pmu.2015.04.003
S9. Energy metabolism, cancer risk, and cancer prevention
Pollak, M. (2008) · European Journal of Cancer Supplements · doi:10.1016/s1359-6349(08)70201-5
Targeting UVB Mediated Signal Transduction Pathways for the Chemoprevention of Squamous Cell Carcinoma
Bowden, G. T., & Alberts, D. S. (2010) · Springer eBooks · doi:10.1007/978-1-4419-7203-3_16
Sum-Based Meta-Analytical Enrichment of Gene Expression Data to Identify Pathway Signatures of Cancers
Wagholikar, K. B., Venkatraman, P., Sundararajan, V., & Kumar‐Sinha, C. (2010) · Journal of Cancer Therapy · doi:10.4236/jct.2010.11006
Insulin allergy in a diabetic patient: Potential factor to increase malignancy incidence
Zhao, H., Yu, S., Wang, Z., Wang, K., Zhang, X., & Lu, Y. (2011) · International Conference on Human Health and Biomedical Engineering · doi:10.1109/hhbe.2011.6027949
The AMPK signalling pathway in cancer and DNA damage
Dandapani, M. (2013) · Discovery Research Portal (University of Dundee)
Cancer et diabète de type 2
Durlach, V. (2011) · Médecine thérapeutique · doi:10.1684/met.2011.0332
DIRECT EFFECTS OF METFORMIN ON PI3K AND RAS SIGNALING IN ENDOMETRIAL CANCER
Iglesias, & David, A. (2012)
Diabetes Mellitus and the Risk for Developing Cancer
Markey, S. M., & Congiusta, M. A. (2013) · International Journal of Experimental Dental Science · doi:10.5005/jp-journals-10029-1038
Insulin receptor and IGF-I receptor Bioactivity in Health and Disease
Varewijck, A. J. (2013) · EUR Research Repository (Erasmus University Rotterdam)
Role of Estradiol, Progestins, Insulines and Adipocytokines in Breast Cancer Promotion in Post-Menopausal Women
Jamin, C. (2010) · Journal of Cancer Therapy · doi:10.4236/jct.2010.11007
Selective Serotonin Reuptake Inhibitors (SSRIs) and Breast Cancer: A Record Linkage Study
Ashbury, J. E. (2008)
Energy Homeostasis and Cancer Prevention: The AMP-Activated
Fay, J. R., Steele, V. E., & Crowell, J. A. (2009)
Identification of TGFβ signaling, p53, and actin stress fibers as targets of LKB1 tumor suppressor activity
Vaahtomeri, K. (2011) · Työväentutkimus Vuosikirja
AMP-Activated Protein Kinase and Cancer Cell Metabolism
Zheng, B., & Cantley, L. C. (2011) · Energy balance and cancer · doi:10.1007/978-1-4419-9911-5_9
Anti-diabetic treatment and cancer occurrence among patients with type II diabetes mellitus
Qiu, H. (2011) · doi:10.7282/t3930s81
La metformina inhibe el crecimiento de células de carcinoma de tiroides, suprime la autorrenovación de las células madre del cáncer y potencia el efecto de los agentes quimioterapéuticos
González, D. C. F. (2012) · Revista de Endocrinología y Nutrición
Antidiabetika und Krebsrisiko beim Pankreaskarzinom
Jakobs, R. (2011)
Konventionelle und kombinierte Insulintherapie bei Typ-2-Diabetes
Janka, H. U. (2006) · Der Diabetologe · doi:10.1007/s11428-006-0064-4
Prevention and Early Detection of Urologic Cancers: A Mini-Review
Aoun, F. Y. (2014) · Medicinal Chemistry · doi:10.4172/2161-0444.s1-006
Metformin and its use in chronic kidney disease, cardiovascular disease and cancer
Sultana, R.-R., & Rice, S. (2015) · InnovAiT Education and inspiration for general practice · doi:10.1177/1755738014563996
Информация об авторах: Власова Ирина Андреевна - доцент, к.м.н., 664049, г. Иркутск, Юбилейный 100, кафедра медицинской реабилитации, тел. (3952) 231312, е-mail: irk_via@mail.ru
Kruchkova, N. V., Bardimova, T. P., Dvornichenko, V. V., & Berezina, M. (2013) · CyberLeninK (CyberLeninka)
Paretoʼs Law and Sulfonylureas
Peiris, A. N., Micklewright, M., & Gangadharan, V. (2007) · Southern Medical Journal · doi:10.1097/smj.0b013e318158b98c
ESTIMATE OF THE INCIDENCE OF ACUTE VIRAL HEPATITIS A IN THE POPULATION OF IRKUTSK REGION
Александрович, А. В., Степаненко, Л. А., & Погорелов, В. И. (2013) · CyberLeninK (CyberLeninka)
Characterizing the Metabolomic Effects of Pancreatic Cancer
Bathe, O. F. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-408103-1.00014-5
Crosstalk between Insulin and Wnt Signaling Pathways
Sun, J. (2010) · TSpace (University of Toronto)
Maladies du pancréas exocrine et diabète
Larger, É., & Lemoine, A. (2013)
AMP-activated protein kinase: a cellular energy sensor with a key role in metabolic disorders and in cancer
Lecture, N. M. (2011)
Diabetes Mellitus: Classification, Symptoms and Management: A Review
Nisha, K. J. (2016) · Research journal of biology
Diabetes and carcinoma
Niebisz, A. J., Kotarski, P., Jasik, M., & Karnafel, W. (2008) · Clinical Diabetology
Bladder Cancer Screening Among Diabetic Patients On Metformin Therapy In A West Africa Subregion
Fakpor, U. M., Ekpe, L. E., & Joshua, O. A. (2016) · Advances in Bioscience and Clinical Medicine · doi:10.7575/aiac.abcmed.16.04.04.01
Effects of Metformin on Breast Cancer Risk and Mortality in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis
Chun, P. (2015) · Korean Journal of Clinical Pharmacy
The Role of p21-activated Protein Kinase 1 in Metabolic Homeostasis
Chiang, Y. P. (2014) · TSpace (University of Toronto)
Investigating Dysregulated Metabolic Pathways that Drive Cancer Pathogenicity
Roberts, L. S. (2017) · eScholarship (California Digital Library)
Metformin as Adjuvant Therapy in Ovarian and Endometrial Cancers
Clark, L. H., & Bae-Jump, V. L. (2017) · Energy balance and cancer · doi:10.1007/978-3-319-63483-8_16
Mapping Dysregulated Metabolic Pathways in Cancer Using Chemoproteomic and Metabolomic Platforms
Louie, S. M. (2017) · eScholarship (California Digital Library)
Chemoprevention of Gastric Cancer: Metformin
Kim, Y., & Cho, S. (2017) · The Korean Journal of Helicobacter and Upper Gastrointestinal Research · doi:10.7704/kjhugr.2017.17.4.179
Плейотропные эффекты метформина: антионкогенное действие (обзор литературы)
Pankiv, V. І. (2013) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.1.49.2013.84051
The Prevention and Control of Cancer by Metformin in Patients with Type 2 Diabetes: A Systematic Mapping ReviewPreprint
Mitchell, A., Price, M., & Cipriano, G. C. (2021) · medRxiv · doi:10.1101/2021.06.04.21258310
Non-hormonal Chemoprevention
Hodde, N. M., & Wood, M. E. (2018) · Current Breast Cancer Reports · doi:10.1007/s12609-018-0294-7
Mechanisms of activation and inhibition of the metabolic regulator AMP-activated protein kinase (AMPK)
Dite, T. A. (2018) · Minerva Access (University of Melbourne)
The Association between Neutrophil to Lymphocyte Ratio and Development of Early Adenomatous Colon Polyps among Middle-Aged and Elderly Individuals in Korea
Kim, J.-H., Cho, A., & Park, B. (2019) · Korean Journal of Family Practice · doi:10.21215/kjfp.2019.9.3.284
Gastrointestinal Cancer Prevention: Diet, Lifestyle, and Therapeutic Prevention
Tran, P. N., & Zell, J. A. (2019) · Springer eBooks · doi:10.1007/978-3-030-18890-0_29
Diabetes with Pancreatic Ductal Adenocarcinoma
Srivani, G., Dariya, B., Alam, A., & Nagaraju, G. P. (2019) · Springer eBooks · doi:10.1007/978-981-32-9393-9_7
Thérapeutique des désordres glycémiques
(2014) · Elsevier eBooks · doi:10.1016/b978-2-294-73954-5.00007-x
Metformin and better survival in type 2 diabetes patients with NSCLC during EGFR‐TKI treatment: Implications of miR‐146a?
Mormile, R. (2020) · The Clinical Respiratory Journal · doi:10.1111/crj.13254
Malignancy Concerns With Antidiabetic Therapies: Examining the Evidence
Lebovitz, H. E. (2010) · Endocrine Practice · doi:10.1016/s1530-891x(20)42872-1
The Effect of Metformin on DNA Damage, Proliferation and Apoptosis in High-Grade Serous Ovarian Cancer Cells
Ciparyte, A. (2020) · Työväentutkimus Vuosikirja
The role of mTOR signalling in translational control and cancer
Dowling, R. J. O. (2009) · eScholarship@McGill (McGill) · doi:10.82308/32572
Investigation of the intrinsic mechanism of drug resistance in multiple myeloma
Ooi, M. G. M. (2011) · Dublin City University Open Access Institutional Repository (Dublin City University)
Diabetes and Cancer
Vigneri, R., & Sciacca, L. (2018) · Endocrinology · doi:10.1007/978-3-319-27316-7_12-1
Thérapeutique des désordres glycémiques
(2019) · Elsevier eBooks · doi:10.1016/b978-2-294-75889-8.00007-5
Diabetes and Cancer
Vigneri, R., & Sciacca, L. (2019) · Endocrinology · doi:10.1007/978-3-319-27316-7_12-2
Current World Literature
(2007) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3280d5f7e9
Diabetes and Cancer
Vigneri, R., & Sciacca, L. (2020) · Endocrinology · doi:10.1007/978-3-030-36694-0_12
Current awareness: Pharmacoepidemiology and drug safety
(2006) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1185
Current literature in diabetes
(2006) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.668
Effect of Immortal Time Bias Controlled Metformin for Cancer Development in Diabetic Patients
Seo, H. J. (2022) · Daehan imsang geon-gang jeungjin hakoeji/Daehan imsang geon'gang jeungjin haghoeji · doi:10.15384/kjhp.2022.22.1.40
Assessing the anticancer effects of metformin
Yunus, M., Zaher, A. E.-S., Hussain, S., Alawami, K. A., Alfaraj, D. J., Alqatari, A. M., Alsalim, M. J., Almissri, M. Z., & Junaid, M. A. L. (2022) · F1000Research · doi:10.12688/f1000research.108827.1
Consensus Reports
(2010) · Diabetes Care · doi:10.2337/dc11-s098
Assessing the anticancer effects of metformin
Yunus, M., Zaher, A. E.-S., Hussain, S., Alawami, K. A., Alfaraj, D. J., Alqatari, A. M., Alsalim, M. J., Almissri, M. Z., & Junaid, M. A. L. (2022) · F1000Research · doi:10.12688/f1000research.108827.2
Effect of metformin on the prognosis of chemoradiotherapy cancer patients: a systematic review and meta-analysis of randomized controlled trials and cohort studiesPreprint
Wang, D., Zhao, P., Dong, X., Ma, H., Yu, M., Yang, K., & Cai, H. (2023) · Research Square · doi:10.21203/rs.3.rs-2633177/v1
Data from Systemic Treatment with the Antidiabetic Drug Metformin Selectively Impairs p53-Deficient Tumor Cell Growth
Buzzai, M., Jones, R. G., Amaravadi, R. K., Lum, J. J., DeBerardinis, R. J., Zhao, F., Viollet, B., & Thompson, C. B. (2023) · doi:10.1158/0008-5472.c.6495702

Authors: Bowker, S. L., Majumdar, S. R., Veugelers, P., & Johnson, J. A.
Affiliations: University of Alberta (CA)
ORCID: Majumdar, Sumit R.
Veugelers, Paul
Johnson, Jeffrey A.
Venue: Diabetes Care
Publisher: American Diabetes Association
Published: 2006-02-01
Volume: 29
Issue: 2
Pages: 254-258
ISSN: 0149-5992 (ISSN-L)
1935-5548
DOI: 10.2337/diacare.29.02.06.dc05-1558
OpenAlex: W2156370651
Cited by: 933
References: 37
Citations by year: 2026: 9 · 2025: 13 · 2024: 28 · 2023: 32 · 2022: 26 · 2021: 25 · 2020: 33 · 2019: 37 · 2018: 33 · 2017: 45 · 2016: 43 · 2015: 52 · 2014: 55 · 2013: 96 · 2012: 93
FWCI: 16.30
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Diabetes Care (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords: type 2 diabetes, cancer mortality, sulfonylureas, insulin therapy, metformin, antidiabetic drugs, cancer risk
MeSH terms: Aged, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Hypoglycemic Agents, Insulin, Male, Metformin, Middle Aged, Neoplasms, Retrospective Studies, Risk Factors, Saskatchewan, Severity of Illness Index, Sulfonylurea Compounds, Cohort Studies, Comorbidity, Multivariate Analysis, Proportional Hazards Models

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Increased Cancer-Related Mortality for Patients With Type 2 Diabetes Who Use Sulfonylureas or Insulin

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks